undamentalytics Newsletter
Sign in

Co-diagnostics, Inc. income statement

In fiscal 2025, Co-diagnostics, Inc. reported revenue of $622,489, down 84.1% on the year before, operating income of −$50.2m (a -8058.8% margin) and net income of −$46.9m, or −$35.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0007598347411
Cost of revenue000171254100
Gross profit0005886293300
Research and development1113151723211920
Selling and marketing01151377422
General and administrative34381214141698
Operating income−5−6−64246−27−43−40−50−49
Interest expense000———————
Income before tax−7−6−64346−19−38−38−49−49
Income tax———09−5−30−2−2
Net income−7−6−64237−14−35−38−47−47
Diluted EPS−$0.63−$0.50−$0.37$1.52$1.23−$0.45−$1.20−$37.22−$35.25—
Diluted shares (average)—————1m—1m1m—
EBITDA−5−6−64246−26−41−39−49−48

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CODX vs ITOCCODX vs PLSECODX vs IMDXCODX vs QTEX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Co-diagnostics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Co-diagnostics, Inc.